Principles of testing for carcinogenic activity

Principles and Methods of Toxicology: Fifth Edition

Volumn , Issue , 2007, Pages 1265-1316

  Williams, Gary M ^a   Iatropoulos, Michael J ^a   Enzmann, Harald G ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Federal Institute for Drugs and Medical Devices BfArM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132687325     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (390)

1. Aardema, M. J. and MacGregor, J. T. (2002): Toxicology and genetic toxicology in the new era of 'toxicogenom-ics': impact of '-omics' technologies. Mutat. Res, 499: 13-25.
2. Abdo, K. M. and Kari, F. W. (1996): The sensitivity of the NTP bioassay for carcinogen hazard evaluation can be modulated by dietary restriction. Exp. Toxicol. Pathol, 48: 129-137.
3. Allaben, W. T., Turturro, A., Leakey, J. E. A., Seng, J. E., and Hart, R. W. (1996): FDA points-to-consider documents: the need for dietary control for the reduction of experimental variability within animal assays and the use of dietary restriction to achieve dietary control. Toxicol. Pathol, 24:776-781.
4. Alexandrov, V. A., Popovich, I. G., Anisimov, V. N., and Napalkov, N. P. (1989): Influence of hormonal disturbances on transplacental and multigeneration carcinogen-esis in rats. In: Perinatal and Multigeneration Carcinogenesis, edited by N. P. Napalkov, J. M. Rice, L. Tomatis, and H. Yamasaki, IARC Publ. No. 96, pp. 35-19. Lyon, France.
5. 1 mice. Environ. Health Perspect., 73:91-106.
6. Alison, R. H., Capen, C. C., and Prentice, D. E. (1994): Neoplastic lesions of questionable significance to humans. Toxicol. Pathol., 22:179-186.
7. Allen, D. G., Pearse, G., Haseman, J. K., and Maronpot, R. R. (2004): Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol., 32:393-401.
8. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M., Eds. (2005): Cancer Statistics 2007, pp. 43-66. American Cancer Society, Atlanta, GA.
9. Apostolou, A. (1990): Relevance of maximum tolerated dose to human carcinogenic risk. Regul. Toxicol. Pharmacol., 11:68-80.
10. Ashby, J. and Tennant, R. W. (1991): Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res., 257:229-306.
11. Baldrick, P. (2005): Carcinogenicity evaluation: comparison of tumor data from dual control groups in the Spra-gue-Dawley rat. Toxicol. Pathol., 33:283-291.
12. Ballard, B. E. (1968): Biopharmaceutical consideration in subcutaneous and intramuscular drug administration. J. Pharmacol. Sci., 57:357-378.
13. Bartow, S. A. (1994): The breast. In: Pathology, edited by E. Rubin and J. L. Farber, pp. 73-992. J.B. Lippincott, Philadelphia, PA.
14. Berenblum, I. (1974): Frontiers of Biology: Carcinogene-sis as a Biological Problem, edited by A. Neuberger and E. L. Tatum, North Holland, Amsterdam.
15. Bergman, K., Olofsson, I.-M., and Sjoeberg, P. (1998): Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat. Regul. Toxicol. Pharmacol., 28: 226-229.
16. Bergeson, L. L. and Auerbach, B. (2004): The Environmental Regulatory Implications of Nanotechnology, Daily Environmental Report No. 71. Bureau of National Affairs, Washington, D.C. (http://www.lawbc.com/other_pdfs).
17. Bischoff, K. B. (1975): Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother. Rep., 59:777-793.
18. Blackburn, K., Stickney, J. A., Carlson-Lynch, H. L., McGinnis, P. M., Chappell, L., and Felter, S. P. (2005): Application of the threshold of toxicological concern approach to ingredients in personal and household care products. Regul. Toxicol. Pharmacol., 43:249-259.
19. /- mouse. Toxicol. Pathol., 27(5):519-527.
20. Bomhard, E. and Rinke, M. (1994): Frequency of spontaneous tumours in Wistar rats in 2-year studies. Exp. Toxicol. Pathol, 46:17-29.
21. Boocock, D. J., Maggs, J. L., Brown, K., White, I. N., and Park, B. K. (2000): Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis, 21(10):1851-1858.
22. Boorman, G. A., Montgomery, Jr., C. A., Eustis, S. L., Wolfe, M. J. McConnell, E. E., and Hardisty, J. F. (1985): Quality assurance in pathology for rodent carcinogenicity studies. In: Handbook of Carcinogen Testing, edited by H. Milman and E. Weisburger, pp. 345-357, Noyes, Park Ridge, NJ.
23. Boorman, G. A., Maronpot, R. R., and Eustis, S. L. (1994): Rodent carcinogenicity bioassay: past, present and future. Toxicol. Pathol., 22:105-111.
24. Boorman, G. A., Haseman, J. K., Waters, M. D., Hardisty, J. F., and Sills, R. C. (2002): Quality review procedures necessary for rodent pathology databases and toxicoge-nomic studies: the National Toxicology Program experience. Toxicol. Pathol. 30(1):88-92.
25. Borowitz, J. L., Moore, P. F., Yim, G. K. W., and Miya, T. S. (1971): Mechanism of enhanced drug effects produced by dilution of the oral dose. Toxicol. Appl. Pharmacol., 19:164-168.
26. Brendler-Schwaab, S., Hartmann, A., Pfuhler, S., and Speit, G. (2005): The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis, 20(4):245-254.
27. Brix, A. E., Nyska, A., Haseman, J. K., Sells, D. M., Jokinen, M. P., and Walker, N. J. (2004): Incidences of selected lesions in control female Harlan Sprague-Dawley rats from two-year studies performed by the National Toxicology Program. Toxicol. Pathol., 33:477-183.
28. Brunnemann, K. D., Enzmann, H. G., Perrone, C. E., Iatro-poulos, M. J., and Williams, G. M. (2002): In ovo carcinogenicity assay (IOCA): evaluation of mannitol, caprolactam and nitrosoproline. Arch. Toxicol., 76:606-612.
29. Brunner, G. H. G., Lamberts, R., and Creutzfeldt, W. (1990): Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion, 47:64-68.
30. Brynes, S. D. (2005): Demystification of 21 CRF Part 556: tolerances for residues of new animal drugs in food. Regulatory Toxicol. Pharmacol., 42:324-327.
31. Butler, W. H., Cohen, S. H., and Squire, R. A. (1997): Mesenchymal tumors of the mouse urinary bladder with vascular and smooth muscle differentiation. Toxicol. Pathol, 25:268-274.
32. Butterworth, B. E., Ashby, J., Bermudez, E., Casciano, D., Mirsalis, J., Probst, G., and Williams, G. (1987): A protocol and guide for the in vivo rat hepatocyte DNA repair assay. Mutat. Res., 189:123-133.
33. Butterworth, B. E. and Goldsworthy, T. L. (1991): The role of cell proliferation in multistage carcinogenesis. Proc. Soc. Exp. Biol. Med., 198:683-687.
34. Calabrese, E. J. (1991): Multiple Chemical Interactions, Lewis, Chelsea, MI.
35. Caldwell, J., Gardner, I., and Swales, N. (1995): An introduction to drug disposition: the basic principles of absorption, distribution, metabolism and excretion. Toxicol. Pathol., 23:148-157.
36. Capen, C. C., Beamer, W. G., Tennant, B. J., and Stitzel, K. A. (1995): Mechanisms of hormone-mediated carcino-genesis of the ovary in mice. Mutat. Res., 333:143-151.
37. Cariello, N. F., Romach, E. H., Colton, H. M., Ni, H., Yoon, L. et al. (2005): Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol. Sci., 88(1):250-264.
38. Cayen, M. N. (1995): Considerations in the design of tox-icokinetic programs. Toxicol. Pathol., 23:148-157.
39. Cayen, M. N. and Black, H. E. (1993): Role of toxicoki-netics in dose selection for carcinogenicity studies. In: Drug Toxicokinetics, edited by P. G. Welling and F. A. de la Iglesia, pp. 69-83. Marcel Dekker, New York.
40. Chappell, W. R. and Mordenti, J. (1991): Extrapolation of toxicological and pharmacological data from animals to humans. Adv. Drug Res., 20:2-116.
41. Chengelis, C. P., Gad, S. C., and Holston, J. (1995): Regulatory Toxicology, Raven Press, New York.
42. Christian, M. S., Hoberman, A. M., Johnson, MD., Brown, W. R., and Bucci, T. J. (1998): Effect of dietary optimization on growth, survival, tumor incidences and clinical pathology parameters in CD Sprague-Dawley and Fischer-344 rats: a 104-week study. Drug Chem. Toxicol., 21: 97-117.
43. Clayson, D. B. and Kitchin, K. T. (1999): Interspecies differences in response to chemical carcinogens. In: Car-cinogenicity, edited by K. T. Kitchin, pp. 837-880. Marcel Dekker, New York.
44. Cohen, S. M. (1998): Urinary bladder carcinogenesis. Toxicol. Pathol., 26:121-127.
45. Cohen, S. M. and Ellwein, L. B. (1991): Genetic errors, cell proliferation, and carcinogenesis. Cancer Res., 51: 6493-6505.
46. Cohen, S. M., Klaunig, J., Meek, M. F., Hill, R. N., Pastoor, T. et al. (2004): Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci., 78:181-186.
47. Conney, A. H. (2003); Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the seventh DeWitt S. Goodman lecture. Cancer Res., 63(21):7005-7031.
48. Contrera, J. F., Jacobs, A. C., Prasanna, H. R., Mehta, M., Schmidt, W. J., and DeGeorge, J. J. (1995): A systemic exposure-based alternative to the maximum tolerated dose for carcinogenicity studies of human therapeutics. J. Am. Coll. Toxicol, 14:1-10.
49. Contrera, J. F., Jacobs, A. C., DeGeorge, J. J., Chen, C., Choudary, J. et al. (1996): Carcinogenicity Testing and the Evaluation of Regulatory Requirements for Pharmaceuticals, Docket No. 96D-0235. U.S. Department of Health and Human Services, Public Health Service, Washington, D.C.
50. Contrera, J. F., Jacobs, A. C., and DeGeorge, J. J. (1997): Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul. Toxicol. Pharmacol, 25:130-145.
51. Contrera, J. F., Matthews, E. J. and Benz, R. D. (2003): Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol., 38:243-259.
52. Cook, J. C., Klinefelter, G. R., Hardisty, J. F., Sharpe, R. M., and Foster, P. M. D. (1999): Rodent Leydig cell tum-origenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit. Rev. Toxicol., 29: 169-261.
53. Cottrell, S., Andrews, C. M., Clayton, D., and Powell, C. J. (1994): The dose-dependent effect of BHT (butylated hydroxytoluene) on vitamin K-dependent blood coagulation in rats. Food Chem. Toxicol., 32(7):589-594.
54. Counts, J. L. and Goodman, J. I. (1995): Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Regul. Toxicol. Pharmacol., 21:418-421.
55. Courtney, C. L., Hawkins, K. L., Meierhenry, E. F., and Graziano, M. J. (1992): Immunohistochemical and ultrastructural characterization of granular cell tumors of the female reproductive tract in two aged Wistar rats. Vet. Pathol., 29:86-89
56. Cox, D. R. (1972): Regression models and life tables. J. R. Stat. Soc., 13:187-220.
57. Crissman, J. W., Goodman, D. G., Hildebrandt, P. K., Maronpot, R. R., Prater, D. A., Riley, J. H., Seaman, W. J., and Thake, D. C. (2004): Best practices guideline: toxicologic histopathology. Toxicol. Pathol., 32:126-131.
58. Cutler, S. J. and Ederer, F. (1958): Maximum utilization of life table method in analyzing survival. J. Chron. Dis., 8:699-712.
59. D'Arcy, P. F. and Harron, D. W. G. (1996): Proceedings, Third International Conference on Harmonization, Yokohama, Japan, 1995.
60. Davies, T. S. and Monro, A. (1994): The rodent carcino-genicity bioassay produces a similar frequency of tumor increases and decreases: implications for risk assessment. Regul. Toxicol. Pharmacol., 20:281-301.
61. Davies, T. S. and Monro, A. (1995): Marketed human pharmaceuticals reported to be tumorigenic in rodents. J. Am. Coll. of Toxicol, 14:90-107.
62. Dedrick, R. L. (1986): Interspecies scaling of regional drug delivery. J. Pharmaceut. Sci, 175:1047-1052.
63. DeGeorge, J. J. and Contrera, J. F. (1996): A regulatory perspective of the guidance on the utility of two rodent species. In: Proc. of the Third Int. Conf. on Harmonization, Yokohama, Japan, 1995, edited by P. F. D'Arcy and D. W. G. Harron, pp. 274-277. Greystone Books, Antrim, North Ireland.
64. De Gruijl, F. R. and Forbes, P. D. (1995): UV-induced skin cancer in a hairless mouse model. BioEssays, 17:651-660.
65. Deschl, U., Kittel, B., Rittinghausen, S., Morawietz, G., Kohler, M., Mohr, U., and Keenan, C. (2002): The value of historical control data: scientific advantages for pathologists, industry and agencies. Toxicol. Pathol., 30(1): 80-87.
66. De Vries, A., von Oostrom, C. Th. M., Dortant, P. M., Beems, R. B., van Kriejl, C. F., Capel, P. J. A., and van Steeg, H. (1997): Spontaneous liver tumours and benzo(a)pyrene-induced lymphomas in XPA-deficient mice. Mol. Carcinog, 19:46-53.
67. Dickinson, D. A., Warnes, G. R., Quievzyn, G., Messer, J., Zhitkovich, A., Rubitski, E., and Aubrecht, J. (2004): Differentiation of DNA reactive and non-reactive genotoxic mechanisms using gene expression profile analysis. Mutat. Res., 549:29-41.
68. Dideriksen, L. H., Jorgensen, L. N., and Drejer, K. (1992): Carcinogenic effect on female rats after 12 month administration of the insulin analogue B10Asp. Diabetes, 41(Suppl. 1):143A (abstract no. 507).
69. Doi, A. M., Hailey, J. R., Hejtmancik, M., Toft, I. J. D., Vallant, M., and Chhabra, R. S. (2005): Topical application of representative multifunctional acrylates produced proliferative and inflammatory lesions in F344/N rats and B6C3F(1) mice, and squamous cell neoplasm in Tg.AC mice. Toxicol. Pathol, 33(6):631-640.
70. Donehower, I., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, Jr., C. A., Butel, J. S., and Bradley, A. (1992): Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature, 356: 215-221.
71. Dragan, Y. P., Rizvi, T., Xu, Y.-H., Hully, J. R., Bawa, N., Campbell, H. A., Maronpot, R. R., and Pitot, H. C. (1991): An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fun-dam. Appl. Toxicol, 16:525-547.
72. Dunnett, C. W. (1955): A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc, 50:1096-1122.
73. Dybing, E., Sanner, T., Roelfzema, H., Kroese, D., and Tennant, R. W. (1997): T25: A simplified carcinogenic potency index: description of the system and study of correlations between carcinogenic potency and species/site specificity and mutagenicity. Pharmacol. Toxicol, 30:272-279.
74. Edwards, R. J., Murray, B. P., Murray, S., Schulz, T., Neubert, D., Gant, T. W., Thorgeirsson, S. S., Boobis, A. R., and Davis, D. S. (1994): Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and humans. Carcinogenesis, 15:829-836.
75. Eiben, R. and Bomhard, E. M. (1999): Trends in mortality, body weights and tumor incidences of Wistar rats over 20 years. Exp. Toxicol. Pathol, 51:523-536.
76. Ellwein, L. G. and Cohen, S. (1990): The health risk of saccharin revisited. CRC Crit. Rev. Toxicol, 20:311-326.
77. Elwell, M. R., Dunnick, J. K., Hailey, J. R., and Haseman, J. K. (1996): Chemicals associated with decreases in the incidence of mononuclear cell leukemia in the Fischer rat. Toxicol. Pathol., 24:238-245.
78. Emerson, C. H., Cohen III, J. H., Young, R. A., Alex, S., and Fan, S.-L. (1990): Gender-related differences of serum thyroxine-binding proteins in the rat. Acta Endocrinol., 123:72-78.
79. Enterline, H. T., Lowry, L. D., and Richman, A. V. (1979): Does malignant hibernoma exist? Am. J. Surg. Pathol., 3:265-271.
80. Enzmann, H., Bomhard, E., Iatropoulos, M. J., Ahr, H. J., Schlueter, G., and Williams, G. M. (1998): Short- and intermediate-term carcinogenicity testing: a review. Part 1. The prototypes mouse skin tumour assay and rat liver focus. Food Chem. Toxicol., 36:979-995.
81. Enzmann, H., Iatropoulos, M. J., Brunnemann, K. D., Bomhard, E., Ahr, H. J., Schlueter, G., and Williams, G. M. (1998): Short- and intermediate-term carcinogenicity testing: a review. Part 2. Available experimental models. Food Chem. Toxicol., 36:997-1013.
82. EEC. (1967): Directive 67/548/EEC with Amendments and Adaptions. Annex VI: Criteria for Classification of Carcinogenic Substances. European Economic Communities, Brussels, Belgium.
83. EEC. (1983): Note for Guidance Concerning the Application of Chapter I(E) of Part 2 of the Annex to Directive 75/398/EEC, with a View to the Granting of a Marketing Authorization of a New Drug. European Economic Communities, Brussels, Belgium.
84. EEC. (1988): Directive 88/379/EEC with Amendments. Annex I: Criteria for Classification of Carcinogenic Substances. European Economic Communities, Brussels, Belgium.
85. EMEA. (2004): CHMPSWP Conclusions and Recommendations on the Use of Genetically Modified Animal Models for Carcinogenicity Assessment. European Medicines Agency, London.
86. EU. (2003): Directive 2003/15/EC of the European Parliament and of the Council 2/27/03 Amending Directive 76/768/EEC on the Approximation of the Laws of the Member States Relating to Cosmetic Products. European Union, Brussels, Belgium (http://europa.eu.int/eur-fex/en/dat/2003/1_D66/1_06620030311en00260035.pdf).
87. Ewing, L. L. (1989): The trophic effect of luteinizing hormone on the rat Leydig cell. J. Am. Coll. Toxicol., 8: 473-485.
88. Faccini, J. M., Abbott, D. P., and Paulus, G. J. J. (1990): Mouse Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies, Elsevier, Amsterdam.
89. Faccini, J. M., Butler, W. R., Friedmann, J.-C., Hess, R., Reznik, G. K., Ito, N., Hayashi, Y., and Williams, G. M. (1992): IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay. Exp. Toxicol. Pathol., 44:443-456.
90. Fairbairn, D. W., Olive, P. L., and O'Neill, K. L. (1995): The comet assay: a comprehensive review. Mutat. Res., 339:37-59.
91. Feinstein, A. R. (1975): Clinical biostatistics. Clin. Pharmacol. Ther., 17:499-513.
92. Fitzgerald, J. M., Boy, V. F., and Manus, A. G. (1984): Formulation of insoluble and immiscible test agents in liquid vehicles for toxicity testing. In: Chemistry for Toxicity Testing, edited by C. W. Jameson and D. B. Walters. Butterworth, Stoneham, MA.
93. Flammang, T. J., von Tungeln, L. S., Kadlubar, F. F., and Fu, P. P. (1997): Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay. Regul. Toxicol. Pharmacol., 26:230-240.
94. Fleiss, J. L. (1981): Statistical Methods for Rates and Proportions, 2nd ed., pp. 145-146. John Wiley & Sons, New York.
95. Fleiss, J. L. (1986): The Design and Analysis of Clinical Experiments, pp. 58-59. John Wiley & Sons, New York.
96. Foran, J. A., Editor. (1997): Principles for the Selection of Doses in Chronic Rodent Bioassays. ILSI Press, Washington, D.C.
97. Forbes, P. D., Sambuco, C. P., and Davies, R. E. (1993): Photocarcinogenesis safety testing. J. Am. Coll. Toxicol., 12:417-424.
98. Forbes P. D. and Sambuco C. P. (1998): Assays for photocarcinogenesis: relevance of animal models. Int. J. Toxicol., 17:577-588.
99. Frantz, S. W., Beatty, P. W., English, J. C., Hundley, S. G., and Wilson, A. G. E. (1994): The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology. Reg. Toxicol. Pharmacol., 19:317-337.
100. Gabriel, K. (1966): Simultaneous test procedures for multiple comparisons on categorical data. J. Am. Stat. Assoc., 61:1081-1096.
101. Gabriel, K. R. (1978): A simple method of multiple comparison of means. J. Am. Stat. Assoc., 73:724-729.
102. Gad, S. C. (1996): Histologic and clinical pathology in the safety assessment and development of new therapeutic agents. Scand. J. Lab. Anim. Sci., 13:325-334.
103. Gad, S. C. and Weil, C. S. (1986): Statistics and Experimental Design for Toxicologists, pp. 1-17. Telford Press, Caldwell, NJ.
104. Galer, D. M. and Monro, A. M. (1998): Veterinary drugs no longer need testing for carcinogenicity in rodent bioassays. Regul. Toxicol. Pharmacol., 28:115-123.
105. Galloway, S. M. et al. (1994): Report from working group on in vitro tests for chromosomal aberrations. Mutat. Res., 312:241-261.
106. Garby, L., Garrow, J. S., Jorgensen, B., Lammert, O., Madsen, K., Sorensen, P., and Webster, J. (1988): Relationship between energy expenditure and body composition in man: specific energy expenditure in vivo of fat and fat-free tissue. Eur. J. Clin. Nutr., 42:301-305.
107. Gart, J. J., Chu, K. C., and Tarone, R. E. (1979): Statistical issues in the interpretation of chronic bioassay tests for carcinogenicity. J. Natl. Cancer Inst., 62:957-974.
108. Gaylor, D. W. and Kodell, R. I. (1999): Dose-response trend tests for tumorigenesis, adjusted for body weight. Toxicol. Sci., 49:318-323.
109. Gehring, P. J., Watanabe, P. G., and Park, C. N. (1978): Resolution of dose response toxicity data for chemicals requiring metabolic activation-example: vinyl chloride. Toxicol. Appl. Pharmacol., 44:581-591.
110. Geyer, H. J., Scheuntert, I., Rapp, K., Kettrup, A., Korte, F., Greim, H., and Rozman, K. (1990): Correlation between acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and total body fat content in mammals. Toxicology, 65(1-2):97-107.
111. Giknis, M. L. A. and Clifford, C. B. (2000): Spontaneous Neoplastic Lesions in the Crl:CD-1® (1CR)BR Mouse. Charles River Laboratories, Worcester, MA.
112. Giknis, M. L. A. and Clifford, C. B. (2003): Spontaneous Neoplasms and Survival in Wistar Han Rats: Compilation of Control Group Data. Charles River Laboratories, Worcester, MA.
113. Giknis, M. L. A. and Clifford, C. B. (2004): Compilation of Spontaneous Neoplastic Lesions and Survival in Crl:CD® (SD) Rats from Control Groups. Charles River Laboratories, Worcester, MA.
114. Gold, L. S. and Zeiger, E. (1996): Handbook of Carcinogenic Potency and Genotoxicity Data Bases. CRC Press, Boca Raton, FL.
115. Gold, L. S. et al. (2005): Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol. Sci., 85:745-808.
116. Gopinath, C., Prentice, D. E., and Lewis, D. J. (1987): Atlas of Experimental Toxicological Pathology. MTP Press, Lancaster, U.K.
117. Grasso, P. and Golberg, L. (1966): Subcutaneous sarcoma as an index of carcinogenic potency. Food Cosmet. Toxicol., 4:297-320.
118. Grasso, P., Sharratt, M., and Cohen, A. J. (1991): Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Annu. Rev. Pharmacol. Toxicol., 31:253-287.
119. Greaves, P. C. (2000): Histopathology of Preclinical Toxicity Studies, 2nd ed. Elsevier, Amsterdam.
120. Greim, H., Gelbke, H. P., Reuter, U., Thielmann, H. W., and Edler, L. (2003): Evaluation of historical control data in carcinogenicity studies. Hum. Exp. Toxicol., 22(10): 541-549.
121. 1 mice from twelve National Toxicology Program two-year carcinogenesis studies. Toxicol. Pathol., 26:602-611.
122. Halliwell, W. H. (1998): Submucosal mesenchymal tumors of the mouse urinary bladder. Toxicol. Pathol., 26:128-136.
123. Halpert, J. R., Guengerich, F. P., Bend, J. R., and Correia, M. A. (1994): Selective inhibitors of cytochrome P450. Toxicol. Appl. Pharmacol., 124:163-175.
124. Hart, R. W., Keenan, K. P., Turturro, A., Abdo, K. M., Leakey, J., and Lyn-Cook, L. (1995): Caloric restriction and toxicology. Fundam. Appl. Toxicol., 25:184-195.
125. Hart, R. W., Neumann, D. A., and Robertson, R. T. (1995): Dietary Restriction: Implications for the Design and Interpretation of Toxicity and Carcinogenicity Studies. ILSI Press, Washington, D.C.
126. Haseman, J. K. (1984): Statistical issues in the design analysis and interpretation of animal carcinogenicity studies. Environ. Health Persp., 58:385-392.
127. Haseman, J. K. (1990): Use of statistical decision rules for evaluating laboratory animal carcinogenicity studies. Fundam. Appl. Toxicol., 14:637-648.
128. Haseman, J. K., Huff, J., and Boorman, G. A. (1984): Use of historical control data in carcinogenicity studies in rodents. Toxicol. Pathol., 2:126-135.
129. Haseman, J. K., Winbush, J. S., and O'Donnell, Jr., M. W. (1986): Use of dual control groups to estimate false positive rates in laboratory animal carcinogenicity studies. Fundam. Appl. Toxicol., 7:573-584.
130. Haseman, J. K. and Rao, G. N. (1992): Effects of corn oil, time-related changes, and inter-laboratory variability on tumor occurrence in control Fischer 344 (F344/N) rats. Toxicol. Pathol., 20:52-60.
131. Haseman, J. K. and Lockhart, A. (1994): The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. Fundam. Appl. Toxicol., 22:382-391.
132. Haseman, J. K. and Johnson, L. (1996): Analysis of National Toxicology Program rodent bioassay data for anticarcinogenic effects. Mutat. Res., 350:131-141.
133. 1 mice in two-year carcinogenicity studies: a National Toxicology Program update. Toxicol. Pathol., 26: 428-441.
134. Haseman, J. K., Ney, E., Nyska, A., and Rao, G. N. (2003): Effect of diet and animal care/housing protocols on body weight, survival, tumor incidences, and nephropathy severity of F344 rats in chronic studies. Toxicol. Pathol., 31: 674-681.
135. Hattis, D., Goble, R., and Chu, M. (2005): Age-related differences in susceptibility to carcinogenesis. II. Approaches for application and uncertainty analyses for individual genetically acting carcinogens. Environ. Health Perspect., 113:509-516.
136. Health and Welfare Canada. (1989): Guidelines for Canadian Drinking Water Quality: Supporting Documentation, Part 1, pp. 1-5. Health and Welfare, Ottawa, Canada.
137. Herman, J. R., Dethloff, L. A., McGuire, E. J., Parker, R. F., Walsh, K. M., Gough, A. W., Masuda, H., and de la Iglesia, F. A. (2002): Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol. Sci. 68:195-235.
138. Hesseltine, G. R., Wolff, R. K., Hanson, R. L., Mauderly, J. L., and McClellan, R. O. (1984): Effect of day vs. night inhalation exposure on lung burdens of galliumoxide in rats. In: Inhalation Toxicology Research Institute Annual Report. Inhalation Toxicology Research Institute, Albuquerque, NM.
139. Hill, R. N., Crisp, T. M., Hurley, P. M., Rosenthal, S. L., and Singh, D. V. (1998): Risk assessment of thyroid follicular cell tumors. Environ. Health Perspect., 106: 447-457.
140. Himms-Hagen, J. (1995): Role of brown adipose tissue thermogenesis in control of thermoregulatory feeding in rats: a new hypothesis that links thermostatic and glucostatic hypotheses for control of food intake. Proc. Soc. Exp. Biol. Med., 208:159-169.
141. Holsapple, M. P., Pitot, H. C., Cohen, S. H., Boobis, A. R., Klaunig, J. E., Pastoor, T., Dellarco, V. L., and Dragan, Y. P. (2006): Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci., 89(1):51-56.
142. Iatropoulos, M. J. (1984): Appropriateness of methods for slide evaluation in the practice of toxicologic pathology. Toxicol. Pathol., 12:4-5.
143. Iatropoulos, M. J. (1988): Society of Toxicologic Pathologists position paper: 'blinded' microscopic examination of tissues from toxicologic or oncogenic studies. In: Carcinogenicity, edited by H. C. Grice and J. L. Ciminera, pp. 133-135. Springer-Verlag, New York.
144. Iatropoulos, M. J. (1993): Comparative histokinetic and xenodynamic considerations in toxicity. In: Drug Toxicokinetics, edited by D. G. P. Welling and F. A. de la Iglesia, pp. 245-266. Marcel Dekker, New York.
145. Iatropoulos, M. J. (1994): Endocrine considerations in toxicologic pathology. Exp. Toxicol. Pathol., 45:391-410.
146. Iatropoulos, M. J., Newman, A. J., Dayan, A. D., Brughera, M., Scampini, G., and Mazue, G. (1994): Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic. Exp. Toxicol. Pathol., 46:265-274.
147. Iatropoulos, M. J., Williams, G. M., Wang, C.-X., and Karlsson, S. H. (1996): New histopathologic and histokinetic methods in preclinical safety studies. Scand. J. Lab. Anim. Sci., 13:339-343.
148. Iatropoulos, M. J. and Williams, G. M. (1996): Proliferation markers. Exp. Toxicol. Pathol., 48:175-181.
149. Iatropoulos, M. and Williams, G. (2004): The function and pathology of brown adipose tissue in animals and humans. J. Toxicol. Pathol., 17:147-153.
150. Imai, K., Yoshimura, S., Yamaguchi, K., Matsui, E., Isaka, H., and Hashimoto, K. (1990): Effects of dietary restriction on age-associated pathological changes in F-344 rats. J. Toxicol. Pathol., 3:209-221.
151. Interdisciplinary Panel on Carcinogenicity (IPC/AIHC). (1984): Criteria for evidence of chemical carcinogenicity. Science, 225:682-687.
152. IARC. (1980): Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal, IARC Monographs Suppl. 2. International Agency for Research on Cancer, Lyon, France.
153. IARC. (1987): IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Preamble, IARC Technical Report No. 87/001. International Agency for Research on Cancer, Lyon, France.
154. IARC. (1990): Complex Mixtures and Cancer Risk, IARC Publ. No. 104. International Agency for Research on Cancer, Lyon, France.
155. IARC. (1992): Mechanisms of Carcinogenesis in Risk Identification, IARC Publ. No. 116. International Agency for Research on Cancer, Lyon, France.
156. IARC. (1992): Solar and Ultraviolet Radiation, IARC Tech. Rep. No. 55. International Agency for Research on Cancer, Lyon, France.
157. IARC. (1995): Peroxisome Proliferation and Its Role in Carcinogenesis: Views and Expert Opinions of an IARC Working Group, IARC Tech. Rep. No. 24. International Agency for Research on Cancer, Lyon, France.
158. IARC. (1996): Directory of Agents Being Tested for Carcinogenicity, IARC Publ. No. 134. International Agency for Research on Cancer, Lyon, France.
159. IARC. (1997): IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vols. 1-69. International Agency for Research on Cancer, Lyon, France.
160. IARC. (1999): The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluations, Consensus Report, IARC Tech. Rep. No. 146, pp. 1-18. International Agency for Research on Cancer, Lyon, France.
161. IARC. (2003): Benzofuran, pp. 27-30; Butylated hydroxy-anisole, pp. 31-40; Dichlorovos, pp. 49-56. In: IARC Monographs in the Predictive Value of Rodent Forestomach and Gastric Neuroendocrine Tumours in Evaluating Carcinogenic Risks to Humans, IARC Tech. Publ. No. 39. International Agency for Research on Cancer, Lyon, France.
162. IARC. (2003): World Cancer Report. International Agency for Research on Cancer, Lyon, France.
163. ICH. (1994): Guideline III/5081 on Toxicokinetics, Commission of the European Communities, Directorate General III: Industry: Industrial Affairs III: Consumer Goods Industries: Pharmaceuticals. International Conference on Harmonization, Brussels, Belgium.
164. ICH. (1996): ICH Harmonized Tripartite Guideline: Impurities in New Drug Products. International Conference on Harmonization, Brussels, Belgium.
165. ICH. (1997): ICH Harmonized Tripartite Guideline: Dose Selection for Carcinogenicity Studies of Pharmaceuticals, Recommended for Adoption of Step 4 of the ICH Process on October 27, 1994, by the ICH Steering Committee and Addendum on the Limit Dose Related to Dose Selection for Carcinogenicity Studies of Pharmaceuticals, Step 4 Consensus Guideline. International Conference on Harmonization, Brussels, Belgium.
166. International Expert Panel on Carcinogen Risk Assessment (IEPCRA). (1996): The use of mechanistic data in the risk assessments of ten chemicals: an introduction to the chemical-specific reviews. Pharmacol. Ther, 71:1-5.
167. International Life Sciences Institute (ILSI); Health and Environmental Sciences Institute (HESI). (2001): Alternatives to carcinogenicity testing. Toxicol. Pathol., 29(Suppl.): 1-351.
168. IPCS. (1996): Butylated hydroxytoluene (BHT). In: Toxicological Evaluation of Certain Food Additives and Contaminants, prepared by the Expert Committee on Food Additives (JECFA) for the 4th Joint Meeting of FAO/WHO, pp. 3-86. International Programme on Chemical Safety, World Health Organization, Geneva.
169. IPCS. (2004): IPCS Risk Assessment Terminology. International Programme on Chemical Safety, World Health Organization, Geneva.
170. International Workshop. (1992): Clinical pathology testing in preclinical safety assessment. Toxicol. Pathol., 20: 469-543.
171. Jacobs, A. (2005): Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? Toxicol. Sci, 88(1):18-23.
172. Jacobs, A., Avalos, J., Brown, P., and Wilkin, J. (1999): Does photosensitivity predict photococarcinogenicity? Int. J. Toxicol, 18:191-198.
173. Jain, R. K., Gerlowski, L. E., Weissbrod, J. M., Wang, J., and Pierson, Jr., R. N. (1981): Kinetics of intake, distribution and excretion of zinc in rats. Ann. Biomed. Eng., 9: 345-361.
174. Jameson, C. W. (1984): Analytical chemistry requirements for toxicity testing of environmental chemicals. In: Chemistry for Toxicity Testing, edited by C. W. Jameson and D. B. Walters, Butterworth, Stoneham, MA.
175. Jonas, A. M., Tomita, Y., and Wyand, D. S. (1965): Enzootic intestinal adenocarcinoma in hamsters. J. Am. Vet. Med. Assoc, 147:1102-1108.
176. Jordan, A. (1992): FDA requirements for nonclinical testing of contraceptive steroids. Contraception., 46:499-509.
177. Karbe, E. (1999): 'Mesenchymal tumor' or 'decidual-like reaction'? Toxicol. Pathol, 27:354-362.
178. Karbe, E., Hartmann, E., George, C., Wadsworth, P., Har-leman, J. and Geiss, V. (1998): Similarities between the uterine decidual reaction and the 'mesenchymal lesion' of the urinary bladder in aging mice. Exp. Toxicol. Pathol., 50:4-6.
179. Kasper, P. (2004): Assessment and acceptance of thresholds of genotoxic impurities in new drug substances: a regulatory perspective. Int. J. Pharmaceut. Med., 18: 209-214.
180. Keenan, K. P. (1996): The uncontrolled variable in risk assessment: ad libitum overfed rodents - fat, facts and fiction. Toxicol. Pathol., 24:376-383.
181. Keenan, K., Smith, P., Hertzog, P., Soper, K., Ballam, G., and Clark, R. (1994): The effects of overfeeding and dietary restriction on Sprague-Dawley rat survival and early pathology biomarkers of aging. Toxicol. Pathol., 22:300-331.
182. Keenan, K. P. Laroque, P., Ballam, G. C., Soper, K. A., Dixit, R., Mattson, B. A., Adams, S. P., and Coleman, J. B. (1996): The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Toxicol. Pathol., 24:757-768.
183. Kelly, W. A., Marler, R. J., and Weikel, J. H. (1993): Drug-induced mesovarial leiomyomas in the rat: a review and additional data. J. Am. Coll. Toxicol., 12: 13-22.
184. Kemp, C. J. (1995): Hepatocarcinogenesis in p53-defi-cient mice. Mol. Carcinog., 12:132-136.
185. Kempson, R. L., Fletcher, C. D. M., Evans, H. L., Hendrickson, M. R., and Sibley, R. K. (2001): Tumours of the Soft Tissues: Atlas of Tumour Pathology, pp. 195-235. AFIP, Washington, D.C.
186. Kier, L. D., Neft, R., Tang, L., Suizu, R., Cook, T., Onsurez, K., Tiegler, K., Sakai, Y., Ortiz, M., Nolan, T., Sankar, U., and Li, A. P. (2004): Applications of microarrays with tox-icologically relevant genes (tox genes) for evaluation of chemical toxicans in Sprague-Dawley rats in vivo and human hepatocytes in vitro. Mutat. Res., 549:101-113.
187. King, F. G., Dedrick, R. L., and Farris, F. F. (1986): Physiological pharmacokinetic modeling of cisdichlorodiamine platinum (II) (DDP) in several species. J. Pharmacokin. Biopharmaceut., 14:131-155.
188. Kirkland, D. J., Aardema, M., Henderson, L., and Müller, L. (2005): Evaluation of the ability of a battery of 3 in vitro genotoxicity tests to discriminate rodent carcinogens and noncarcinogens. I. Sensitivity, specificity and relative predictivity. Mutat. Res., 584:1-256.
189. Kirkland, D. J., Henderson, L., Marzin, D., Müller, L., Parry, J. M., Speit, G., Tweats, D. J., and Williams, G. M. (2005): Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes. Mutat. Res., 588: 88-105.
190. Klaassen, C. D. (1999): The role of diet and caloric intake in aging, obesity and cancer. Toxicol. Sci., 2(Suppl.): 1-146.
191. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C. et al. (2003): PPAR-alpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol., 33(6):655-780.
192. Klopman, G. and Rosenkranz, H. S. (1994): Approaches to SAR in carcinogenesis and mutagenesis: prediction of carcinogenicity/mutagenicity using MULTICASE. Mutat. Res., 305:33-46.
193. Knapka, J. J. (1979): Laboratory animal feed. Science, 204: 1367-1368.
194. Komulainen, H. (1996): Pharmacokinetic experiments in animals: needs and application of data. Scand. J. Lab. Anim. Sci., 23:315-316.
195. Krewski, D., Smythe, R. T., Dewanji, A., and Colin, D. (1988): Statistical tests with historical controls. In: Carci-nogenicity, edited by H. C. Grice and J. L. Ciminera, pp. 23-38. Springer-Verlag, New York.
196. Kripke, M. L. (1994): Ultraviolet radiation and immunology: something new under the sun (Presidential address). Cancer Res., 54:6102-6105.
197. Kroes, R. and Wester, P. W. (1986): Forestomach carcinogens: possible mechanisms of action. Food Chem. Toxicol., 24:1083-1089.
198. Kroes, R., Renwick, A. G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., van Schothorst, F., Vos, J. G., and Wurtzen, G. (2004): Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol., 42(1):65-83.
199. Kunze, E. and Chowaniec, J. (1990): Tumors of the urinary bladder. In: Pathology of Tumours in Laboratory Animals. Vol. I. Tumors of the Rat, IARC Publ. No. 99, pp. 345-373. International Agency for Research on Cancer, Lyon, France.
200. Lai, Y. L., Jacoby, R., and Jonas, A. (1978): Age related and light associated retinal changes in Fischer rats. Invest. Ophthalmol. Vis. Sci., 17:634-638.
201. Lavbelin, G., Roba, J., Roncucci, R., and Parmentier, R. (1975): Carcinogenicity of 6-aminochrysene in mice. Eur. J. Cancer, 11:327-334.
202. Le Boeuf, R. A., Kerckaert, G. Aardema, M., Gibson, D., Brauninger, R., and Isfort, R. (1996): The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mutat. Res., 356: 85-127.
203. Leder, A., Kuo, A., Cardiff, R. D., Sinn, E., and Leder, P. (1990): v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. U.S.A., 87:9178-9182.
204. Lee, P. (1988): Assumptions in analyses of the bioassay: a statistician's view. In: Carcinogenicity, edited by H. C. Grice and J. L Ciminera, pp. 1-10. Springer-Verlag, New York.
205. Lehman, A. J. and Fitshugh, O. G. (1954): Ten-fold safety factor studies. U.S. Q. Bull., XVIII (1):33-35.
206. Leung, H. W. and Paustenbach, D. J. (1988): Application of pharmacokinetic to derive biological exposure indexes from threshold limit values. Am. Indust. Hyg. Assoc., 49: 445-450.
207. Lington, A. W., Bird, M. G., Plutnick, R. T., Stubblefield, W. A., and Scala, R. A. (1997): Chronic toxicity and carcinogenic evaluation of diisonoyl phthalate in rats. Fundam. Appl. Toxicol., 36:79-89.
208. Long, G. G., Symanowski, J. T., and Roback, K. (1998): Precision in data acquisition and reporting of organ weights in rats and mice. Toxicol. Pathol., 26:316-318.
209. Lutz, W. K. (1986): Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens. J. Cancer Res. Clin. Oncol., 112: 85-91.
210. MacDonald, J., French, J. E., Gerson, R. J., Goodman, J., Inoue, T. et al. (2004): The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. Toxicol. Sci., 77:188-194.
211. MacDonald, J. S. (2004): Human carcinogenic risk evaluation. Part IV. Assessment of human risk of cancer from chemical exposure using a global weight-of-evidence approach. Toxicol. Sci., 82:3-8.
212. Mahler, J. F., Stokes, W., Mann, P. C., Takaoka, M., and Maronpot, R. R. (1996): Spontaneous lesions in aging FVB/N mice. Toxicol. Pathol., 24:710-716.
213. Mahler, J. P., Flagler, N. D., Malarkey, D. E., Mann, P. C., Haseman, J. K., and Eastin, W. (1998): Spontaneous and chemically-induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol. Pathol., 26: 501-511.
214. Maita, K., Hirano, M., Harada, T., Mitsumori., K., Yoshida, A., Takahashi, K., Nakashima, N., Kitazawa, T., Enomoto, A., Inui, K., and Shirasu, Y. (1988): Mortality, major cause of moribundity, and spontaneous tumors in CD-1 mice. Toxicol. Pathol., 16:340-349.
215. -/-, and wild-type mice during 9 months' dietary exposure. Toxicol. Pathol., 33:609-620.
216. McClellan, R. O. and Hobbs, C. H. (1986): Generation, characterization and exposure systems for test atmospheres. In: Safety Evaluation of Chemicals, edited by W. E. Lloyd. Hemisphere, Washington, D.C.
217. McConnell, E. E. (1983): Pathology requirements for rodent two year studies. I. A review of current procedures. Toxicol. Pathol., 11:60-64.
218. McConnell, E. E., Solleveld, H. A., Swenberg, J. A., and Boorman, G. A. (1986): Guidelines of combining neoplasms for evaluation of rodent carcinogenesis studies. J. Natl. Cancer Res., 76:283-289.
219. McConnell, R. F. (1989): General observations on the effects of sex steroids in rodents with emphasis on longterm oral contraceptive studies. In: Safety Requirements for Contraceptive Steroids, edited by F. Michael, pp. 211-229. Cambridge University Press, New York.
220. McConnell, R. F., Westen, H. H., Ulland, B. M., Bosland, M. C., and Ward, J. M. (1992): Proliferative lesions of the testes in rats with selected examples from mice. In: Guides for Toxicologic Pathology. STP/ARP/AFIP, Washington, D.C.
221. McMartin, D. N. Sahota, P. S., Gunson, D. E., Hsu, H. H., and Spaet, R. H. (1992): Neoplasms and related proliferative lesions in control Sprague-Dawley rats from carcinogenicity studies: historical data and diagnostic considerations. Toxicol. Pathol., 20:212-225.
222. McQueen, C. A. and Williams, G. M. (1987): The hepatocytes primary culture/DNA repair test using hepatocytes from several species. Cell Biol. Toxicol., 3:209-218.
223. McQueen, C. A. and Williams, G. M. (1988): Genotoxicity of carcinogens in human hepatocytes: application in hazard assessment. Toxicol. Appl. Pharmacol., 96:360-366.
224. Milman, H. A. and Weisburger, E. K. (1985): Handbook of Carcinogen Testing. Noyes, Park Ridge, NJ.
225. MHW. (1989): Guidelines for Toxicity Studies Required for Applications for Approved To Manufacture (Import) Drugs: Carcinogenicity Study. Ministry of Health and Welfare, Tokyo, Japan.
226. Modlin, I. M. and Sachs, G. (1998): Age-Related Diseases: Biology and Treatment, pp 242-245. Schnetztor-Verlag GmbH, Konstanz, Germany.
227. Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2005): Nanomedicine: current status and future prospects. FASEB J., 19:311-330.
228. Monro, A. (1992): What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? Toxicol. Appl. Pharmacol., 112:171-181.
229. Monro, A. (1993): How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? Adv. Drug React. Toxicol. Rev., 12:5-34.
230. Monro, A. (1996): Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp. Toxicol. Pathol., 48:155-166.
231. Morrison, V. and Ashby, J. (1994): A preliminary evaluation of the performance of the Muta Mouse (bac Z) and Big Blue (bac I) transgenic mouse mutation assays. Mutagenesis, 9:367-376.
232. Mugford, C. A. and Kedderis, G. L. (1998): Sex-dependent metabolism of xenobiotics. Drug Metab. Rev., 30(3): 441-498.
233. Mulder, G. J. (1986): Sex differences in drug conjugation and their consequences for drug toxicity: sulfation, glucu-ronidation and glutathione conjugation. Chem. Biol. Interact., 57:1-15.
234. Munro, I. C. (1977): Considerations in chronic testing: the chemical, the dose, the design. J. Environ. Pathol. Toxicol., 1:183-197.
235. Munro, I. C., Ford, R. A., Kennepohl, E., and Sprenger, J. G. (1996): Thresholds of toxicological concern based on structure-activity relationships. Drug Metab. Rev., 28: 209-217.
236. NCI. (1994): Survey of Compounds Which Have Been Tested for Carcinogenic Activity, NIH Publ. 94-3765. National Cancer Institute Washington, D.C.
237. NIH. (1981): NIH Guidelines for the Laboratory Use of Chemical Carcinogens: NIH Publ. 81-2385. National Institutes of Health, Washington, D.C.
238. NIH. (1986): Humane Care and Use of Laboratory Animals, NIH Publ. 86-23. National Institutes of Health, Washington, D.C.
239. National Research Council. (1983): Risk Assessment in the Federal Government: Managing the Process. National Academy Press, Washington, D.C.
240. National Research Council. (1993): Use of Maximum Tolerated Dose in Animal Bioassays for Carcinogenicity. National Academy Press, Washington, D.C.
241. National Research Council. (1996): Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, D.C.
242. 1 Mice, NTP Tech. Rep. 460, NIH Publ. No. 97-3376, pp. 1-411. National Toxicology Program, Research Triangle Park, NC.
243. NTP. (2000): Report on Carcinogens, Ninth Edition: Carcinogen Profiles 2000. Prepared by Technology Planning and Management Corporation, Durham, NC.
244. NTP. (2005): NTP Technical Reports Index. National Toxicology Program, Research Triangle Park, NC.
245. Nelson, D. R., Koymans, L., Kamatski, T., Stegeman, J. J., Feyereisen, R. et al. (1996): P450 superfamily: update on new sequences, gene mapping accession numbers and nomenclature. Pharmacogenetics, 6:1-42.
246. Neumann, H.-G. (1986); The role of DNA damage in chemical carcinogenesis of aromatic amines. J. Cancer Res. Clin. Oncol., 112:100-106.
247. Newberne, P. M. and de la Iglesia, F. A. (1985): Philosophy of blind slide reading in toxicologic pathology. Toxicol. Pathol., 13:225.
248. Newberne, P. M. and Sotnikov, A. V. (1996): Diet: the neglected variable in chemical safety evaluations. Toxicol. Pathol., 24:746-756.
249. Nicholls, I., Kolopp, M., Pommier, F., and Scheiwiller, M. (2005): The presence of drug in control samples during toxicokinetic investigations: a Novartis perspective. Reg. Toxicol. Pharmacol., 42:172-178.
250. Noble, J. F. (1984): Automated data acquisition systems in the 80s and beyond. II. Operation. In: Toxicology Laboratory Design and Management for the 80s and Beyond, edited by A. Tegeris, pp. 143-158. Karger, New York.
251. Oberdörster, G., Oberdörster, E., and Oberdörster, J. (2005): Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect, 113:823-839.
252. Office of Science and Technology Policy. (1985): Chemical carcinogens: a review of the science and its associated principles. Fed. Reg., 50(184):10371-10442.
253. Office of Technology Assessment. (1987): Identifying and Regulating Carcinogens: A Background Paper, pp. 1-251. U.S. Congress, Washington, D.C.
254. Olsen, J. H., Schulgen, G., Boice, J. D., Whysner, J., Travis, L. B., Williams, G. M., Johnson, F. B., and O'McGee, J. (1995): Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res., 55:294-297.
255. Oppenheimer, E. T., Willhite, M., Stout, A. F., Damishofsky, I., and Fishman, M. M. (1964): A comparative study of the effects of embedding cellophane and polystyrene films in rats. Cancer Res, 24:379-386.
256. OECD. (1981): Adopted Guidelines for Testing of Chemicals. Section 4. Health Effects, No. 451, Carcinogenicity Studies. Organization of Economic Cooperation and Development, Paris, France.
257. OECD. (OECD) (1998): Principles of Good Laboratory Practices, ENV/mc/CHEM(98)17. Organization of Economic Cooperation and Development, Paris, France.
258. Ozaki, M., Ozaki, K., Watanabe, T., Uwagawa, S., Okuno, Y., and Shirai, T. (2005): Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains. Toxicol. Pathol, 33:267-271.
259. Parkinson, A. (2001): Biotransformation of Xenobiotics. In: Casarett & Doull's Toxicology, 6th ed., edited by C. D. Klaassen, pp. 133-224. McGraw-Hill, New York.
260. Peck, C. C., Barr, W. H., and Benet, L. Z. (1992): Opportunities for integration of pharmacokinetics, pharmacody-namics and toxicokinetics in rational drug design. J. Pharmaceut. Sci, 81:605-610.
261. Perrone, C. E., Shao, L., and Williams, G. M. (1998): Effect of rodent hepatocarcinogenic peroxisome prolifer-ators on fatty acyl-CoA oxidase, DNA synthesis, and apo-ptosis in cultured human and rat hepatocytes. Toxicol. Appl. Pharmacol., 150:277-286.
262. Perrone, C., Ahr, H.-J., Duan, J. D., Jeffrey, A. M., Schmidt, U., Williams, G. M., and Enzmann, H. G. (2004): Embryonic turkey liver: activities of biotransformation enzymes and cultivation of DNA-reactive carcinogens. Arch. Toxicol., 78:589-598.
263. Peto, R., Pike, M. C., Day, N. E., Gray, R. G., Lee, P. N., Parish, S., Peto, J., and Wahrendorf, J. (1980): Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal, edited by R. Montesano, H. Bartsch, and L. Tomatis, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Suppl. 2, pp. 311-426. International Agency for Research on Cancer, Lyon, France.
264. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N. (1984): A proposed general convention for the numerical description of carcinogenic potency of chemicals in chronic-exposures animal experiments. Environ. Health Perspect, 58:1-8.
265. 32P-postlabeling assay. Mutat. Res., 378(102):1-12.
266. PDR. (2005): Bone marrow metabolism, pp. 1840-1844; Recombinant human insulin (Lantus), pp. 715-719; Tamoxifen, pp. 622, 2966. In: Physician's Desk Reference, edited by L. Murray. Thompson PDR, Montvale, NJ.
267. Poteracki, J. and Walsh, K. M. (1998): Spontaneous neoplasms in control Wistar rats: a comparison of reviews. Toxicol. Sci., 45:1-8.
268. Poulet, F. M., Berardi, M. R., Halliwell, W., Hartman, B., Auletta, C., and Bolte, H. (2004): Development of hiber-nomas in rats dosed with phentolamine mesylate during the 24-month carcinogenicity study. Toxicol. Pathol., 32(5):558-566.
269. Powles, P. (1996): Interpretation of data from toxicokinetic studies. Scand. J. Lab. Anim. Sci., 23:317-323.
270. Prahalada, S., Majka, J. A., Soper, K. A., Nett, T. M., Bagdon, W. J., Peter, C. P., Burek, J. D., MacDonald, J. S., and van Zwieten, M. J. (1994): Leydig cell hyperplasia and adenomas in mice treated with finasteride, a 5α-reductase inhibitor: possible mechanism. Fundam. Appl. Toxicol., 22: 211-219.
271. 32P-postlabeling test for DNA damage. Proc. Natl. Acad. Sci. U.S.A., 78:626-6129.
272. Rao, G. N., Piegorsch, W. W., and Haseman, J. K. (1987): Influence of body weight on the incidence of spontaneous tumors in rats and mice of long-term studies. Am. J. Clin. Nutr., 45:252-260.
273. 1) mice during a nine year period. Toxicol. Pathol, 18:71-77.
274. Registry of Industrial Toxicology Animal Data (RITA). (1999): Optimization of carcinogenicity bioassays. Exp. Toxicol. Pathol., 51:461-475.
275. Reuter, J. and Hobbelen, H. (1977): The effect of continuous light exposure on the retina in albino and pigmented rats. Physiol. Behav., 18:939-944.
276. Rice, J. M., Williams, G. M., Palmer, A. E., London, W. T., and Sly, D. L. (1981): Pathology of gestational chorio-carcinoma induced in patas monkeys by ethylnitrosourea given during pregnancy. Placenta, 3(Suppl.):223-230.
277. Rice, J. M., Baan, R. A., Blettner, M., Genevois-Char-neau, C., Grosse, Y., McGregor, D. B., Partensky, C., and Wilbourn, J. D. (1999): Rodent tumors of urinary bladder, renal cortex, and thyroid gland in IARC monographs evaluation of carcinogenic risk to humans. Toxicol. Sci., 49:166-171.
278. Riley, V. (1975): Mouse mammary tumors: alteration of incidence as apparent function of stress. Science, 189: 465-467.
279. Riley, V. (1981): Psychoneuroendocrine influences on immune-competence and neoplasia. Science, 212: 1100-1109.
280. Robens, J. F., Calabrese, E. J., Piegorsch, W. W., Schueler, R. L., and Hayes, A. W. (1994): Principles of testing for carcinogenicity. In: Principles and Methods of Toxicology, 3rd ed., edited by A. W. Hayes, pp. 697-728. Raven Press, New York.
281. Rosai, J. (1981): Breast. In: Ackerman's Surgical Pathology, pp. 1098-1149. Mosby, St. Louis, MO.
282. Russo, J., Russo, I. H., Rogers, A. E., Van Zwieten, M. J., and Gusterson, B. (1990): Tumours of the mammary gland. In: Pathology of Tumours in Laboratory Animals. Vol. I. Tumors of the Rat, edited by V. S. Turusov and U. Mohr, IARC Publ. No. 99, pp. 47-78. International Agency for Research on Cancer, Lyon, France.
283. Saitoh, A., Kimura, M., Takahashi, R., Yokoyama, M., Nomura, T., Izawa, M., Sekiya, T., Nishimura, S., and Katsuki, M. (1990): Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene, 5:1195-1200.
284. Sambuco, C. P., Davies, R. E., Forbes, P. D., and Hober-man, A. M. (1991): Photocarcinogenesis and consumer product testing: technical aspects. Toxicol. Methods, 1: 75-83.
285. Sansone, E. B. and Losikoff, A. M. (1978): Contamination from feeding volatile test chemicals. Toxicol. Appl. Pharmacol., 46:703-708.
286. Sansone, E. B. and Tewari, Y. B. (1978): Penetration of protective clothing materials by 1,2-dibromo-3-chloropro-pane, ethylene dibromide, and acrylonitrile. J. Am. Indust. Hyg. Assoc., 39:921-922.
287. Sansone, E. B. and Tewari, Y. B. (1978): The permeability of laboratory gloves to selected solvents. J. Am. Indust. Hyg. Assoc., 39:169-174.
288. Sasahara, K., Ando-Lu, J., Nishiyama, K., Takahashi, M., Yoshida, M., and Maekawa, A. (1998): Granular cell foci of the uterus in Donryu rats. J. Comp. Pathol, 119: 195-199.
289. Sasaki, Y. F., Izumiyama, F., Nishidate, E., Matsusaka, N., and Tsuda, S. (1997): Detection of rodent liver carcinogen genotoxicity by the alkaline single-cell gel electrophoresis (comet) assay in multiple mouse organs (liver, lung, spleen, kidney, and bone marrow). Mutat. Res., 391:201-214.
290. Scheuplein, R. J. and Blank, I. H. (1971): Permeability of the skin. Physiol. Rev, 51:702-743.
291. Schmid, W. (1975): The micronucleus test. Mutat. Res, 31:9-15.
292. SCCNFP. (2003): Updated Recommended Strategy for Testing Hair Dyes for their Potential Genotoxicity/Mutagenicity/Carcinogenicity, SCCNFP/0720/03. Scientific Committee on Cosmetic and Non-Food Products Intended for Consumers, Brussels, Belgium.
293. Seifter, E., Rettura, G., Zisblatt, M., Levenson, S M., Levine, N., Davidson, A., and Seigter, J. (1973): Enhancement of tumor development of physically-stressed mice inoculated with an oncogenic virus. Experientia, 29: 1379-1882.
294. 1 mice and F344 rats. Fundam. Appl. Toxicol., 24:247-259.
295. Serabian, M. A. and Pilaro, A. M. (1999): Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol. Pathol., 27:27-31
296. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P. et al. (1992): Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J. Pharmaceut. Res, 81:309-312.
297. Shirai, T., Hirose, M., and Ito, N. (1999): Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals. In: The Use of Short- and MediumTerm Tests for Carcinogenic Hazard Evaluation, edited by D. B. McGregor, J. M. Rice, and S. Venitt, IARC Publ. No. 146, pp. 251-271. International Agency for Research on Cancer, Lyon, France.
298. Sieber, S. M. and Adamson, R. H. (1978): Long-term studies on the potential carcinogenicity of artificial sweeteners in non-human primates. In: Health and Sugar Substitutes, edited by B. Guggenheim, pp. 266-271. Karger, Basel, Switzerland.
299. Silva, L. B. and van der Laan, J. W. (2000): Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul. Toxicol. Pharmacol, 32:135-143.
300. Smith, D. M., Rogers, A. E., and Newberne, P. M. (1975): Vitamin A and benzo(a)pyrene carcinogenesis in the respiratory tract of hamsters fed a synthetic diet. Cancer Res., 35:1485-1488.
301. Smith, D. M., Ortiz, L. W., Archuleta, R. F., Spalding, J. F., Tillery, M. I., Ettinger, H. J., and Thomas, R. G. (1981): A method of chronic nose-only exposures of laboratory animals to inhaled fibrous aerosols. In: Inhalation Toxicology and Technology, edited by H. P. Leong, pp. 89-105. Ann Arbor Science, Ann Arbor, MI.
302. Son, W. C. and Gopinath, C. (2004): Early occurrence of spontaneous tumors in CD-1 mice and Sprague-Dawley rats. Toxicol. Pathol., 32:371-374.
303. Sontag, J. R., Page, N. P., and Safiotti, U. (1976): Guidelines for Carcinogen Bioassay in Small Rodents. DHHS Publ. (NIH)76-801. National Cancer Institute, Bethesda, MD.
304. Spalding, J. W., French, J. E., Tice, R. R., Furedi-Machek, M., Haseman, J. K., and Tennant, R. W. (1999): Development of a transgenic mouse model for carcinogenesis bio-assays: evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol. Sci., 49:241-254.
305. Stammberger, I., Bube, A., Durchfeld-Meyer, B., Donaubauer, H., and Troschau, G. (2002): Evaluation of the carcinogenic potential of insulin glargine (Lantus) in rats and mice. Int. J. Toxicol., 21:171-179.
306. /- Hemizygous knockout mouse: overview of the available data. Toxicol. Pathol., 29(Suppl):30-50.
307. 1 mice. Toxicol. Pathol., 16:321-326.
308. Tarone, R. E. (1975): Tests for trend in life table analysis. Biometrika, 62:679-682.
309. Tennekes, H., Gembardt, C., Dammann, M., and van Raven-zwaay, B. (2004): The stability of historical control data for common neoplasms in laboratory rats: adrenal gland (medulla), mammary gland, liver, endocrine pancreas, and pituitary gland. Regul. Toxicol. Pharmacol, 40(1):18-27.
310. Tennekes, H., Kaufmann, W., Dammann, M., and van Ravenzwaay, B. (2004): The stability of historical control data for common neoplasms in laboratory rats and the implications for carcinogenic risk assessment. Regul. Tox-icol. Pharmacol, 40(3):293-304.
311. Thake, D. C., Iatropoulos, M. J., Hard, G. C., Hotz, K. J., Wang, C.-X., Williams, G. M., and Wilson, A. G. E. (1995): A study of the mechanism of butachlor-associated gastric neoplasms in Sprague-Dawley rats. Exp. Toxicol. Pathol., 47:107-116.
312. Thomas, G. A. and Williams, E. D. (1991): Evidence for and possible mechanisms of non-genotoxic carcinogenesis in the rodent thyroid. Mutat. Res., 248:357-370.
313. Thorgiersson, U., Dalgard, D., Reeves, J., and Adamson, R. (1994): Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul. Toxicol. Pharmacol., 19:130-151.
314. Thurman, J. D., Bucci, T. J., Hart, R. W., and Torturro, A. (1994): Survival, body weight, and spontaneous neoplasms in ad libitum-fed and food-restricted Fischer-344 rats. Toxicol. Pathol., 22:1-9.
315. Tomatis, L. (1989): Overview of perinatal and multigeneration carcinogenesis. In: Perinatal and Multigeneration Carcinogenesis, edited by N. P. Napalkov, J. M. Rice, L. Tomatis, and H. Yamasaki, IARC Publ. No. 96, pp. 1-15. International Agency for Research on Cancer, Lyon, France.
316. Trayhurn, P. (1993): Brown adipose tissue: from thermal physiology to bioenergetics. J. Biosci., 18:161-173.
317. Tsuda, H., Park, C. B., and Moore, M. A. (1999): Shortand medium-term carcinogenicity tests. In: The Use of Short- and Medium-Term Tests for Carcinogenic Hazard Evaluation, edited by D. B. McGregor, J. M. Rice, and S. Venitt, IARC Publ. No. 146, pp. 203-249. International Agency for Research on Cancer, Lyon, France.
318. Tuch, K., Ockert, D., Hauschke, D., and Christ, B. (1992): Comparison of the ECL-cell frequency in the stomachs of 3 different rat strains. Pathol. Res. Pract., 188:672-675.
319. Tucker, R. W. and Barrett, J. C. (1986): Decreased number of spindle and cytoplasmic microtubules in hamster embryo cells treated with a carcinogen, diethylstilbestrol. Cancer Res., 46:2088-2095.
320. Tugwood, J. D. and Elcombe, C. R. (1999): Predicting carcinogenicity: peroxisome proliferators. In: Carcinoge-nicity, edited by K. T. Kitchin, pp. 337-360. Marcel Dekker, New York.
321. 1 mouse. Toxicol. Pathol., 24:769-775.
322. Turusov, V. S. (1994): Histiocytic sarcoma. In: Pathology of Tumours in Laboratory Animals. Vol. II. Tumors of the Mouse, edited by V. S. Turusov and U. Mohr, IARC Publ. No. 111, pp. 671-680. International Agency for Research on Cancer, Lyon, France.
323. Turusov, V. S., Torii, M., Sills, R. C., Willson, G. A., Herbert, R. A., Hailey, J., Haseman, J. K., and Boorman, G. A. (2002): Hepatoblastomas in mice in the U.S. National Toxicology Program (NTP studies). Toxicol. Pathol., 30:580-591.
324. U.S. Congress. (1985): Animal Welfare Act, CFR 9, Parts 1, 2, 3.
325. U.S. Congress. (1996): Food Quality Protection Act, Public Law 104-170.
326. U.S. Congress. (1998): Food Quality Protection Act Amendment, Public Law 105-324.
327. U.S. Department of Agriculture. (1989): Animal Welfare Rules, CFR 9, Parts 1, 2.
328. U.S. DHW. (1977): Guide for Care and Use of Laboratory Animals, Publ. No. NIH 77-23. U.S. Department of Health and Welfare, Washington, D.C.
329. U.S. EPA. (1986): Guidelines for carcinogen risk assessment. Fed. Reg, 51:33992-34005.
330. U.S. EPA (1990): Good Automated Practices, Draft 12-28-90. Scientific Systems Staff, Office of Information Resources Management U.S. Environmental Protection Agency, Washington, D.C.
331. U.S. EPA. (1991): Alpha 2μ-Globulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the Male Rat, Risk Assessment Forum, EPA/625/3-91/019F. U.S. Environmental Protection Agency, Washington, D.C. 332. U.S. EPA. (1992): A cross-species scaling factor for carcinogen risk assessment based on equivalence of mg/kg/day: notice. Fed. Reg., 57:24152-24173.
332. U.S. EPA. (1992): Guidelines for exposure assessment. Fed. Reg., 57:22888-22938.
333. U.S. EPA. (1996): Proposed guidelines for carcinogen risk assessment. Fed. Reg., 61:17960-18011.
334. U.S. EPA. (1997): Exposure Factors Handbook, EPA/600/P-95-002A. Office of Research and Development, U.S. Environmental Protection Agency, Washington, D.C.
335. U.S. EPA. (2003): Final Draft Guidelines for Carcinogenic Risk Assessment, EPA/630/P-03/001A. U.S. Environmental Protection Agency, Washington, D.C. (www.epa.gov/ncea/raf/cancer2003.htm).
336. U.S. EPA. (2005): Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens, pp. 1-42. U.S. Environmental Protection Agency, Washington, D.C.
337. U.S. FDA. (1978): Good Laboratory Practices for nonclinical laboratory studies, Code of Federal Regulations, Title 21, Part 58. Fed. Reg, 43:59986-60025.
338. U.S. FDA. (1993): Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food (Redbook II). U.S. Food and Drug Administration, Washington, D.C.
339. U.S. FDA. (1993): Advisory committee for protocols for safety evaluation, panel on carcinogenesis: report on cancer testing in the safety of food additives and pesticides. Toxicol. Appl. Pharmacol., 20:419-438.
340. U.S. FDA. (1994): International Conference on Harmonization, draft guideline on dose selection for carcinogenicity studies of pharmaceuticals. Fed. Reg., 59:9752-9760 (http://www.ifpma.org/ich5s.html).
341. U.S. FDA. (1994): General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals. Center for Veterinary Medicines, U.S. Food and Drug Administration, Washington, D. C.
342. U.S. FDA. (1995): Food additives: threshold of regulation for substances used in food contact articles. Fed. Reg., 60:36582-36596.
343. U.S. FDA. (1997): International Conference on Harmonization, guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals. Fed. Reg, 62:61515-61519 (http://www.iben.gov).
344. U.S. FDA. (1997): International Conference on Harmonization, guidelines on impurities in new drug products. Fed. Reg., 62:27454-27461.
345. U.S. FDA. (2001): Guidance for Industry: Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals. U.S. Food and Drug Administration, Washington, D.C.
346. U.S. FDA. (2002): Revision of the definition of the term 'no residue' in the new animal drug regulations. Fed. Reg., 67:78172-78174.
347. U.S. FDA. (2004): Guidance for Industry: Recommended Approaches to Integration of Genetic Toxicology Study Results, pp. 1-6. U.S. Food and Drug Administration, Washington, D.C.
348. Utzat, C. D., Clement, C. C., Ramos, L. A., Das, A., Tomasz, M., and Basu, A. K. (2005): DNA adduct of the mitomycin C metabolite 2,7-diaminonitrosene is a non-toxic and nonmutagenic DNA lesion in vitro and in vivo. Chem. Res. Toxicol., 18:213-223.
349. van Oosterhout, J. P. J., van der Laan, J. W., de Waal, E. J., Olejniczak, K., Hilgenfeld, M., Schmidt, V., and Bass, R. (1997): The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul. Toxicol. Pharmacol., 25:6-17.
350. van Steeg, H., Klein, H., Beems, R. B., and van Kreijl, C. F. (1998): Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing. Toxicol. Pathol., 26:742-749.
351. Vessel, E. S. (1967): Induction of drug metabolizing enzymes in liver microsomes of mice and rats by softwood bedding. Science, 157:1057-1058.
352. Viollon-Abadie, C., Lassere, D., Debruyne, E., Nicod, L., Carmichael, N., and Richert, L. (1999): Phenobarbital, β-naphthoflavone, clofibrate, and pregnenolone-16a-carbon-itrile do not affect hepatic thyroid hormone UDP-glucu-ronosyl transferase activity, and thyroid gland function in mice. Toxicol. Appl. Pharmacol, 155:1-12.
353. Walsh, K. M. and Poteracki, J. (1994): Spontaneous neoplasms in control Wistar rats. Fundam. Appl. Toxicol., 23: 65-72.
354. Wattenberg, L. W. (1985): Chemoprevention of cancer. Cancer Res., 45:1-8.
355. Weisburger, E. K. (1983): History of the bioassay program of the National Cancer Institute. Prog. Exp. Tumor Res., 26:187-201.
356. Weisburger, J. H. and Williams, G. M. (1981): Carcinogen testing: current problems and new approaches. Science, 214:401-407, 1981.
357. Weisburger, J. H. and Williams, G. M. (1984): Bioassay of carcinogens: in vitro and in vivo tests. In: Chemical Carcinogenesis, Vol. 2, 2nd ed., ACS Monograph 182, pp. 1323-1373. American Chemical Society, Washington, D.C.
358. Weisburger, J. H. and Williams, G. M. (1995): Causes of cancer. In: American Cancer Society Textbook of Clinical Oncology, edited by G. P. Murphy, W. Lawrence, Jr., and R. E. Lenhard, Jr., pp. 10-39. American Cancer Society, Atlanta, GA.
359. Weiss, S. W. and Goldblum, J. R. (2001): Benign lipomatous tumors and liposarcoma. In: Soft Tissue Tumors, pp. 571-695. Mosby, St. Louis, MO.
360. Whysner, J. and Williams, G. M. (1992): International cancer risk assessment: the impact of biologic mechanisms, Regul. Toxicol. Pharmacol., 15:41-50.
361. Whysner, J. and Williams, G. M. (1996): Butylated hydroxyanisole mechanistic data and risk assessment: conditional species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther, 71(1/2): 137-151.
362. Whysner, J., Ross, P. M., and Williams, G. M. (1996): Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther., 71(1/2):153-191.
363. Williams, G. M. (1987): Definition of a human cancer hazard. In: Nongenotoxic Mechanisms in Carcinogenesis, Banbury Report 25, pp. 367-380. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
364. Williams, G. M. (1989): Methods for evaluating chemical genotoxicity. Ann. Rev. Pharmacol. Toxicol., 29:189-211.
365. Williams, G. M. (1989): Interactive carcinogenesis in the liver. In: Liver Cell Carcinoma, edited by P. Bannasch, D. Keppler, and G. Weber, Falk Symposium 51, pp. 197-216. Kluwer, Boston, MA.
366. Williams, G. M. (1990): Screening procedures for evaluating the potential carcinogenicity of food-packaging chemicals. Regul. Toxicol. Pharmacol., 12:30-40.
367. Williams, G. M. (1992): DNA reactive and epigenetic carcinogens. Exp. Toxicol. Pathol., 44:457-464.
368. Williams, G. M. (1997): Chemicals with carcinogenic activity in the rodent liver; a mechanistic evaluation of human risk. Cancer Lett., 118:1-14.
369. Williams, G. M. (1999): Chemical-induced preneoplastic lesions in rodents as indicators of carcinogenic activity. In: The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluations, edited by D. B. McGregor, J. M. Rice, and S. Venitt, IARC Publ. No. 146, pp. 185-202. International Agency for Research on Cancer, Lyon, France.
370. Williams, G. M. (1999): Mechanistic considerations in cancer risk assessment. Inhal. Toxicol., 11:549-554.
371. Williams, G. M. and Furuya, K. (1984): Distinction between liver neoplasm promoting and syncarcinogenic effects demonstrated by exposure to phenobarbital or diethylnitrosamine either before or after N-2-fluorenylac-etamide. Carcinogenesis, 5:171-174.
372. Williams, G. M. and Weisburger, J. H. (1991): Chemical carcinogenesis. In: Toxicology: The Basic Science of Poisons, edited by M. O. Amdur, J. Doull, and C. D. Klaassen, pp. 127-200. Pergamon Press, New York.
373. Williams, G. M. and Perone, C. (1996): Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. In: Peroxisomes: Biology and Role in Toxicology and Disease, Vol. 804, edited by J. K. Reddy, T. Suga, G. P. Mannaerts, P. B. Lazarow, and S. Subramani, pp. 554-572. The New York Academy of Sciences, New York.
374. Williams, G. M. and Jeffrey, A. M. (2000): Oxidative DNA damage: endogenous and chemically induced. Regul. Toxicol. Pharmacol., 32:283-292.
375. Williams, G. M. and Iatropoulos, M. J. (2001): Principles of testing for carcinogenic activity. In: Principles and Methods of Toxicology, 4th ed., edited by A. Wallace Hayes. Taylor & Francis, Philadelphia, PA, pp. 959-1000.
376. Williams, G. M. and Iatropoulos, M. J. (2002): Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol. Pathol., 30: 41-53.
377. Williams, G. M., Chandrasekaran, V., Katayama, S., and Weisburger, J. H. (1981): Carcinogenicity of 3-methyl-2-naphthylamine and 3,2'-dimethyl-4-aminobiphenyl to the bladder and gastrointestinal tract of the Syrian golden hamster with atypical proliferative enteritis. J. Natl. Cancer Inst., 67:481-488.
378. Williams, G. M., Laspia, M. F., and Dunkel, V. C. (1982): Reliability of the hepatocyte primary culture/DNA repair test in testing of coded carcinogens and non carcinogens. Mutat. Res., 97:359-370.
379. Williams, G. M., Mori, H., and McQueen, C. A. (1989): Structure-activity relationships in the rat hepatocyte DNA-repair test for 300 chemicals. Mutat. Res, 221:263-286.
380. Williams, G M., Iatropoulos, M. J., and Weisburger, J. H. (1996): Chemical carcinogen mechanisms of action and implications for testing methodology. Exp. Toxicol. Pathol, 48:101-111.
381. Williams, G. M., Karbe, E., Fenner-Crisp, P., Iatropoulos, M. J., and Weisburger, J. H. (1996): Risk assessment of carcinogens in food with special consideration of nongenotoxic carcinogens. Exp. Toxicol. Pathol., 48:209-215.
382. Williams, G. M., Iatropoulos, M. J., Jeffrey, A. M., Luo, F. Q., Wang, C.-X., and Pittman, B. (1999): Diethylnitrosamine exposure-response for DNA ethylation, hepatocellular proliferation and initiation of carcinogenesis in rat liver display non-linearities and thresholds. Arch. Toxicol., 73:394-402.
383. Williams. G. M., Iatropoulos, M. J., and Whysner, J. (1999): Safety assessment of butylated hydroxyanisole and butylated hydroxytoluene as antioxidant in food additives. Food Chem. Toxicol, 37:1027-1038.
384. Williams, G. M., Iatropoulos, M. J., and Jeffrey, A. M. (2002): Anticarcinogenicity of monocyclic phenolic compounds. Eur. J. Cancer Prev, 11(Suppl. 2):S101-S107.
385. Williams, G. M, Iatropoulos, M. J., and Jeffrey, A. M. (2005): Thresholds for DNA-reactive (genotoxic) organic carcinogens. J. Toxicol. Path., 18:69-77.
386. Wiltse, J. and Dellarco, V. L. (1996): U.S. Environmental Protection Agency guidelines for carcinogen risk assessment: past and future. Mutat. Res, 365:3-15.
387. WHO. (1969): Principles for the Testing and Evaluation of Drugs for Carcinogenicity, WHO Technical Report Series No. 426. World Heath Organization, Geneva.
388. Wutzler, P. and Thust, R. (2001): Genetic risks of antiviral nucleoside analogues: a survey. Antiviral Res., 49:55-74.
389. Yamamoto, S., Urano, K., Koizumi, H., Wakana, S., Hioki, K., Mitsumori, K., Kurokawa, Y., Hayashi, Y., and Nomura, T. (1998): Validation of transgenic mice in carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ. Health Perspect, 106:57-69.
390. Zeiger, R. (1998): Identification of rodent carcinogens and non-carcinogens using genetic toxicity tests: premises, promises, and performance. Regul. Toxicol. Pharmacol., 28:85-95.